Daxor Corp Files 8-K on Security Holder Vote Matters
Ticker: DXR · Form: 8-K · Filed: Jul 18, 2024 · CIK: 27367
| Field | Detail |
|---|---|
| Company | Daxor Corp (DXR) |
| Form Type | 8-K |
| Filed Date | Jul 18, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
Related Tickers: DAXR
TL;DR
DAXR filed an 8-K for a shareholder vote event on 7/15.
AI Summary
Daxor Corporation filed an 8-K on July 18, 2024, reporting that the earliest event reported was on July 15, 2024. The filing pertains to the submission of matters to a vote of security holders. The company's principal executive offices are located at 107 Meco Lane, Oak Ridge, TN 37830.
Why It Matters
This filing indicates that Daxor Corporation is engaging in a process that requires shareholder approval, which could lead to significant corporate actions or changes.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote matter and does not inherently indicate immediate financial distress or significant operational changes.
Key Players & Entities
- Daxor Corporation (company) — Registrant
- July 15, 2024 (date) — Earliest event reported date
- July 18, 2024 (date) — Filing date
- 107 Meco Lane, Oak Ridge, TN 37830 (location) — Principal executive offices address
FAQ
What specific matters are being submitted for a vote of security holders?
The filing does not specify the exact matters to be voted on, only that it is a submission of matters to a vote of security holders.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on July 15, 2024.
What is the primary purpose of this Form 8-K filing?
The primary purpose is to report the submission of matters to a vote of security holders.
Where are Daxor Corporation's principal executive offices located?
Daxor Corporation's principal executive offices are located at 107 Meco Lane, Oak Ridge, TN 37830.
What is the Commission File Number for Daxor Corporation?
The Commission File Number for Daxor Corporation is 811-22684.
Filing Stats: 843 words · 3 min read · ~3 pages · Grade level 14.6 · Accepted 2024-07-18 14:46:28
Key Financial Figures
- $0.01 — ange on which registered Common Stock $0.01 par value DXR Nasdaq Indicate by
Filing Documents
- form8-k.htm (8-K) — 48KB
- form8-k_001.jpg (GRAPHIC) — 2KB
- 0001493152-24-028308.txt ( ) — 222KB
- dxr-20240715.xsd (EX-101.SCH) — 3KB
- dxr-20240715_lab.xml (EX-101.LAB) — 33KB
- dxr-20240715_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. DAXOR CORPORATION (Registrant) Date: July 18, 2024 By: /s/ Robert J. Michel Name: Robert J. Michel Title: Chief Financial Officer About Daxor Corporation Daxor Corporation (Nasdaq: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions including heart failure and critical care by better informing treatment strategies, resulting in significantly better patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients. For more information please visit our website at Daxor.com . Forward-Looking Certain of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to p